Development of a model to demonstrate the impact of National Institute of Health and Care Excellence cost‐effectiveness assessment on health utility for targeted medicines

Abstract

Advancing medical knowledge and technologies are increasing understanding of patient heterogeneity. Patients previously thought to have the same disease and treated homogeneously can be discovered instead to have subtle differences and respond differently to different treatments (Bieber, 2013;Padmanabhan, 2014